A Phase 3 interventional study of DLBS3233 and Metformin XR in Prediabetes, sponsored by Dexa Medica Group. Completed at 2 sites in Indonesia. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy.
DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.
There will be 3 groups of treatment; each group will consist of 40 subjects with the treatment regimens for 12 weeks:
Treatment I : 1 capsule of DLBS3233 1000 mg once daily; Treatment II : 2 capsules of DLBS3233 100 mg once daily; Treatment III : 1 tablet of Metformin XR 500 mg twice daily
Subjects will be asked to come to the clinic and will be evaluated for treatment efficacy at Baseline and at 4-week intervals over the 12-week course of therapy. Throughout the 12-week therapy, subjects should record the product consumption and adverse event occurred during the study in the provided Patient's Diary.
The safety profile of study medication other than vital signs and adverse event will be measured at Baseline and End of Study.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
This study's enrollment of 120 is above the median of 62 across 762 interventional studies indexed under Prediabetic State.
Browse Prediabetic State studies →Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 capsule of DLBS3233 100 mg once daily
Drug: DLBS3233
2 capsules of DLBS3233 100 mg once daily
Drug: DLBS3233
1 tablet of Metformin XR 500 mg twice daily
Drug: Metformin XR
DLBS3233 will be given into two different groups; 1 capsule of DLBS3233 100 mg once daily and 2 capsules of DLBS3233 100 mg once daily.
Also known as: Inlacin
Metformin XR 500 mg will be given 1 tablet twice daily as a comparator.
Changes of HbA1c levels
Changes of HbA1c levels from Baseline to Week 12 of study treatment.
Time frame: 12 weeks
Changes of Fasting Plasma Glucose (FPG) levels
Changes of FPG levels from Baseline to Week 4, 8, and 12 of study treatment.
Time frame: 4, 8, and 12 weeks
Changes of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values
Changes of HOMA-IR values from Baseline to Week 12 of study treatment
Time frame: 12 weeks
Changes in Homeostatic Model Assessment of β-cell function (HOMA-β) values
Changes of HOMA-β values from Baseline to Week 12 of study treatment
Time frame: 12 weeks
Changes of Waist Circumference
Changes of Waist Circumference from Baseline to Week 4, 8, and 12 of study treatment
Time frame: 4, 8, 12 weeks
Changes of Body Mass Index (BMI)
Changes of BMI from Baseline to Week 4, 8, and 12 of study treatment
Time frame: 4, 8, 12 weeks
Liver function (alanine transaminase [ALT])
Concentration of alanine transaminase (ALT) serum at Week 4, 8, and 12 of study treatment
Time frame: 4, 8, and 12 weeks
Renal function (estimated Glomerular Filtration Rate [eGFR])
eGFR evaluation at Week 4, 8, and 12 of study treatment
Time frame: 4, 8, and 12 weeks
Adverse events
Adverse event, will be observed throughout the study conduct
Time frame: 4, 8, and 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Oct 2026, 15 months.
Of 18 phase 3 interventional studies under Prediabetic State, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 40. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DLBS3233